High-rolling investors have positioned themselves bullish on DexCom (NASDAQ:DXCM), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include ...

DexCom's stock fell sharply after mixed Q2 earnings and lowering full-year guidance, signaling a revaluation phase with lower growth expectations. Revenue guidance was cut from $4.2-$4.35 billion to ...

Dexcom has rebounded since my last update, but I maintain a 'Hold' rating due to continued overvaluation and limited upside potential. Growth remains solid, especially in sensors and U.S. expansion, ...